Comparative Pharmacology
Head-to-head clinical analysis: BECLOMETHASONE DIPROPIONATE versus BREZTRI AEROSPHERE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BECLOMETHASONE DIPROPIONATE versus BREZTRI AEROSPHERE.
BECLOMETHASONE DIPROPIONATE vs BREZTRI AEROSPHERE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Beclomethasone dipropionate is a corticosteroid that exerts anti-inflammatory, antipruritic, and vasoconstrictive effects through binding to glucocorticoid receptors, leading to inhibition of phospholipase A2, reduced prostaglandin and leukotriene synthesis, and suppression of inflammatory cytokines.
Budesonide is a corticosteroid with anti-inflammatory activity; glycopyrrolate is a muscarinic receptor antagonist that inhibits cholinergic bronchoconstriction; formoterol is a long-acting beta2-adrenergic agonist that relaxes bronchial smooth muscle.
Inhalation: 40-320 mcg twice daily (DPI or pMDI); maximum 640 mcg/day. Intranasal: 1-2 sprays (42-84 mcg) per nostril twice daily. Topical: Apply 0.025% cream/ointment twice daily.
Two inhalations (each containing budesonide 160 mcg, glycopyrrolate 18 mcg, and formoterol fumarate 4.8 mcg) orally twice daily.
None Documented
None Documented
Clinical Note
moderateBeclomethasone dipropionate + Gatifloxacin
"The risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Gatifloxacin."
Clinical Note
moderateBeclomethasone dipropionate + Rosoxacin
"The risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Rosoxacin."
Clinical Note
moderateBeclomethasone dipropionate + Levofloxacin
"The risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Levofloxacin."
Clinical Note
moderateTerminal elimination half-life is 2.8-3.1 hours after inhalation, with a slower phase attributed to slow dissolution from lung tissue; clinical context: supports twice-daily dosing.
Terminal elimination half-life: budesonide 2.5–3.1 hours, glycopyrrolate 0.5–1.0 hour (inhalation) or 1.3–1.6 hours (IV), formoterol approximately 10 hours after inhalation. Clinical context: Budesonide's short half-life supports once-daily dosing with the co-suspension delivery technology providing prolonged lung retention. Glycopyrrolate's short half-life necessitates twice-daily dosing; formoterol's longer half-life allows twice-daily administration.
Primarily fecal (via bile) as metabolites, ~60-70%; renal excretion accounts for <10% of unchanged drug.
Following oral inhalation, budesonide (corticosteroid component) is primarily excreted in urine (60%) and feces (40%) as metabolites. Glycopyrrolate (LAMA) is excreted predominantly unchanged in urine (70%) and feces (30%) after IV administration, with renal excretion as the main route. Formoterol (LABA) is extensively metabolized; approximately 62% of a radiolabeled dose appears in urine and 24% in feces. For the fixed-dose combination, renal elimination of unchanged glycopyrrolate is a major clearance pathway.
Category A/B
Category C
Inhaled Corticosteroid
Inhaled Corticosteroid/LAMA/LABA Combination
Beclomethasone dipropionate + Trovafloxacin
"The risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Trovafloxacin."